<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01881217</url>
  </required_header>
  <id_info>
    <org_study_id>16182</org_study_id>
    <nct_id>NCT01881217</nct_id>
  </id_info>
  <brief_title>First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors</brief_title>
  <official_title>An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous BAY 1179470 in Subjects With Advanced, Refractory Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, non-randomized, Phase I dose-escalation study designed to assess the safety,
      tolerability, pharmacokinetics(PK) /pharmacodynamics( PD) and tumor response profile of
      BAY1179470 in subjects with advanced, refractory solid tumors
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2013</start_date>
  <completion_date type="Actual">August 16, 2016</completion_date>
  <primary_completion_date type="Actual">March 18, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum drug concentration versus time curve (AUC) from zero to infinity after single (first) and multiple doses of BAY1179470</measure>
    <time_frame>Cycle 1 and 2: pre-dose, 0.5, 1 , 2, 3, 5, 8, 24, 48, 72, 168 and 336 hours after start of the infusion, Cycle 3 and 4: pre-dose and 1 hour after start of the infusion; each cycle is 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum drug concentration (Cmax) and minimal drug concentration (Cmin) of BAY1179470 in plasma after single and multiple dose administration</measure>
    <time_frame>Cycle 1 and 2: pre-dose, 0.5, 1 , 2, 3, 5, 8, 24, 48, 72, 168 and 336 hours after start of the infusion, Cycle 3 and 4: pre-dose and 1 hour after start of the infusion; each cycle is 21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Every 42 days</time_frame>
    <description>Tumor response will be evaluated based on the RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker (plasma)</measure>
    <time_frame>Cycle 1: pre-dose, 24 hours after start of the infusion and Day 15, Cycle 2, 3 and 4: pre-dose; each cycle is 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker (biopsy)</measure>
    <time_frame>Cycle 1: pre-dose and Day 8; cycle 1 is 21 days</time_frame>
    <description>Additional cohort only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Cycle 1 and Cycle 2 pre-dose and every second cycle thereafter pre-dose. End of treatment visit and follow-up visit up to 2 years; each cycle is 21 days</time_frame>
    <description>Analyzed for anti-BAY 1179470 antibodies</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>BAY1179470 (Dose escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1179470 (additional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1179470 (expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1179470</intervention_name>
    <description>BAY1179470 will be administered as a 1-hour intravenous infusion.</description>
    <arm_group_label>BAY1179470 (Dose escalation)</arm_group_label>
    <arm_group_label>BAY1179470 (additional)</arm_group_label>
    <arm_group_label>BAY1179470 (expansion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with advanced, histologically or cytologically confirmed solid tumors
             refractory to any standard therapy or have no standard therapy available or subjects
             actively refuse any treatment which would be regarded standard

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1 and a life
             expectancy of at least 3 months

          -  Adequate bone marrow, liver, and renal function.

        For subjects in the additional cohort:

          -  Subjects with advanced, histologically or cytologically confirmed gastric cancer.

          -  At least moderate FGFR2 expression in the tumor tissue from archival samples is
             confirmed

        Exclusion Criteria:

          -  History of severe allergic reactions to monoclonal antibody therapy

          -  Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mm Hg and/or
             diastolic blood pressure &gt; 90 mmHg, despite optimal medical management

          -  Any condition that is unstable or could jeopardize the safety of the subject and his /
             her compliance in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kita-Adachigun</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2013</study_first_submitted>
  <study_first_submitted_qc>June 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>Advanced, refractory solid tumors</keyword>
  <keyword>FGFR2</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

